Carisma Therapeutics, Inc. (CARM)

Market Cap	16.92M
Revenue (ttm)	19.96M
Net Income (ttm)	-50.77M
Shares Out	41.79M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,152,580
Open	0.3704
Previous Close	0.3916
Day's Range	0.3690 - 0.4100
52-Week Range	0.1417 - 1.7000
Beta	2.79
Analysts	Hold
Price Target	0.90 (+122.28%)
Earnings Date	Aug 7, 2025

About CARM

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: CARM
• Website: https://www.carismatx.com

Financial Performance

In 2024, Carisma Therapeutics's revenue was $19.63 million, an increase of 31.59% compared to the previous year's $14.92 million. Losses were -$60.48 million, -30.39% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for CARM stock is "Hold." The 12-month stock price target is $0.9, which is an increase of 122.28% from the latest price.

Price Target

$0.9

(122.28% upside)

Analyst Consensus: Hold